Cancers de l’adolescent

  • Emmanuel Désandes
Chapter

Abstrait

L’adolescence est une période de transition marquée par une maturation progressive physique, sexuelle, psychologique et sociale et l’acquisition d’une autonomie qui font de lui un adulte (1, 2). Cette période de développement correspond en règle à la période de 12 à 19 ans. Conformément à la définition établie par l’Organisation mondiale de la santé (OMS), elle englobe dans une large mesure la période pré- et péripubertaire, de 10 à 14–15 ans, dominée par les changement corporels, et inclut la phase de socialisation et d’émancipation, de 15 à 19 ans (3). En épidémiologie, les registres pédiatriques de population concernent les cas de cancer survenant de 0 à 14 ans révolus au moment du diagnostic. Aussi, dans ce chapitre, nous nous intéressons à la tranche d’âge 15–19 ans afin de présenter les données complémentaires touchant les cancers des adolescents.

This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. 1.
    Alvin P, Marcelli D (2005) Partie 1: L’adolescence, puberté et sexualité. Chapitre 1: L’adolescence, les adolescents. In: Marcelli D (ed) Médecine de l’adolescent (2e édition). Masson, Paris, p 3–8Google Scholar
  2. 2.
    Sacks D (2003) Age limits and adolescents. Paediatr Child Health 8: 577–8Google Scholar
  3. 3.
    Organisation mondiale de la santé (1986) Les jeunes et la santé: défi pour la société: Rapport d’un groupe d’étude de l’OMS sur la jeunesse et la santé pour tous d’ici l’an 2000. Série de Rapports techniques, no 731. Organisation mondiale de la santé, GenèveGoogle Scholar
  4. 4.
    Péquignot F, Jougla E, Le Toullec A et al. (2000) Mortalité par suicide chez les jeunes en France en 1997 et évolution depuis 1980. Bull Epidemiol Hebd 9: 1–5Google Scholar
  5. 5.
    Alvin P (2005) Partie 1: L’adolescence, puberté et sexualité. Chapitre 2: Les adolescents et leur santé en chiffres. In: Marcelli D (ed) Médecine de l’adolescent (2e édition). Masson, Paris, p 15–28Google Scholar
  6. 6.
    Kramarova E, Stiller CA (1996) The international classification of chilhood cancer. Int J Cancer 68: 759–65PubMedCrossRefGoogle Scholar
  7. 7.
    Gatta G, Zigon G, Capocaccia R et al. (2008) Survival of European children and young adults with cancer diagnosed 1995–2002. Eur J Cancer: SubmittedGoogle Scholar
  8. 8.
    Steliarova-Foucher E, Stiller C, Kaatsch P et al. (2004) Geographical patterns and time trends of cancer incidence and survival among children and adolescents in Europe since the 1970s (the ACCISproject): an epidemiological study. Lancet 364: 2097–105PubMedCrossRefGoogle Scholar
  9. 9.
    Stiller CA, Desandes E, Danon SE et al. (2006) Cancer incidence and survival in European adolescents (1978–1997). Report from the Automated Childhood Cancer Information System project. Eur J Cancer 42: 2006–18PubMedCrossRefGoogle Scholar
  10. 10.
    Ries LAG, Harkins D, Krapcho M et al. (2006) SEER Cancer Statistic Review, 1975–2003, National Cancer Institute, Bethesda: MD. http://seer.cancer.gov/csr/1975_2003Google Scholar
  11. 11.
    Desandes E, Lacour B, Sommelet D et al. (2004) Cancer incidence among adolescents in France. Pediatr Blood Cancer 43: 742–8PubMedCrossRefGoogle Scholar
  12. 12.
    Stiller CA (2007) International patterns of cancer incidence in adolescents. Cancer Treat Rev 33: 631–45PubMedCrossRefGoogle Scholar
  13. 13.
    Howe HL, Wu X, Ries LA et al. (2006) Annual report to the nation on the status of cancer, 1975–2003, featuring cancer among U.S. Hispanic/Latino populations. Cancer 107: 1711–42PubMedCrossRefGoogle Scholar
  14. 14.
    Parkin DM, Whelan SL, Ferlay J et al. (2002) Cancer incidence in five continents (Volume VII). IARC, LyonGoogle Scholar
  15. 15.
    Desandes E, Clavel J, Berger C et al. (2004) Cancer incidence among children in France, 1990–1999. Pediatr Blood Cancer 43: 749–57PubMedCrossRefGoogle Scholar
  16. 16.
    Desandes E, Lacour B, Beiot A et al. (2007) Cancer incidence and survival among adolescents and young adults in France (1978–1997). Bull Cancer 94: 331–7PubMedGoogle Scholar
  17. 17.
    Bleyer A, O’Leavy M, Barr R et al. (2006) Cancer epidemiology in older adolescents and young adults 15 to 29 years of age, including SEER incidence and survival: 1975–2000. National Cancer Institut, SEER Program. NIH Pub. No. 06-5767, Bethesda, MDGoogle Scholar
  18. 18.
    Steliarova-Foucher E, Stiller C, Lacour B et al. (2005) International Classification of Childhood Cancer, third edition. Cancer 103: 1457–67PubMedCrossRefGoogle Scholar
  19. 19.
    Yeoh EJ, Ross ME, Shurtleff SA et al. (2002) Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell 1: 133–43PubMedCrossRefGoogle Scholar
  20. 20.
    Schiffer CA (2003) Differences in outcome in adolescents with acute lymphoblastic leukemia: a consequence of better regimens? Better doctors? Both? J Clin Oncol 21: 760–1PubMedCrossRefGoogle Scholar
  21. 21.
    Pui CH, Evans WE (1998) Acute lymphoblastic leukemia. N Engl J Med 339: 605–15PubMedCrossRefGoogle Scholar
  22. 22.
    Ribera JM, Ortega JJ, Oriol A et al. (2002) Prognostic value of karyotypic analysis in children and adults with high-risk acute lymphoblastic leukemia included in the PETHEMA ALL-93 trial. Haematologica 87: 154–66PubMedGoogle Scholar
  23. 23.
    Groupe Francais de Cytogenetique Hematologique (1996) Cytogenetic abnormalities in adult acute lymphoblastic leukemia: correlations with hematologic findings outcome. A Collaborative Study of the Group «FranÇais de Cytogénétique Hématologique». Blood 87: 3135–42Google Scholar
  24. 24.
    van den Berg H, van der Lelie J (2000) Acute lymphoblastic leukaemia in puberty and adolescence. Ann Oncol 11: 1375–9PubMedCrossRefGoogle Scholar
  25. 25.
    Uckun FM, Reaman G, Steinherez PG et al. (1996) Improved clinical outcome for children with T-lineage acute lymphoblastic leukemia after contemporary chemotherapy: a Children’s Cancer Group Study. Leuk Lymphoma 24: 57–70PubMedCrossRefGoogle Scholar
  26. 26.
    Boucheix C, David B, Sebban C et al. (1994) Immunophenotype of adult acute lymphoblastic leukemia, clinical parameters, and outcome: an analysis of a prospective trial including 562 tested patients (LALA87). French Group on Therapy for Adult Acute Lymphoblastic Leukemia. Blood 84: 1603–12PubMedGoogle Scholar
  27. 27.
    Barry E, DeAngelo DJ, Neuberg D et al. (2007) Favorable outcome for adolescents with acute lymphoblastic leukemia treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols. J Clin Oncol 25: 813–9PubMedCrossRefGoogle Scholar
  28. 28.
    Seeker-Walker LM, Craig JM, Hawkins JM et al. (1991) Philadelphia positive acute lymphoblastic leukemia in adults: age distribution, BCR breakpoint and prognostic significance. Leukemia 5: 196–9Google Scholar
  29. 29.
    Pui CH, Crist WM, Look AT (1990) Biology and clinical significance of cytogenetlc abnormalities in childhood acute lymphoblastic leukemia. Blood 76: 1449–63PubMedGoogle Scholar
  30. 30.
    Ribera JM, Oriol A, Sanz MA et al. (2008) Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the Programa Espanol de Tratamiento en Hematologia pediatric-based protocol ALL-96. J Clin Oncol 26: 1843–9PubMedCrossRefGoogle Scholar
  31. 31.
    Pein F, Valteau-Couanet D, Bénard J et al. (2008) Neuroblastome. In: Kalifa C, Pein F, Oberlin O et al. (eds) Cancers de l’enfant. Flammarion Médecine-Sciences, Paris, p 203–18Google Scholar
  32. 32.
    Brodeur GM, Castelberry RP (1997) Neuroblastoma. In: Pizzo PA, Pollack DG (eds) Principles and practice of pédiatrie oncology, third edition. Lippincott-Raven Publishers, Philadelphia, p 761–97Google Scholar
  33. 33.
    Schwab M, Shimada H, Joshi V et al. (2000) Neuroblastic tumours of adrenal gland and sympathie nervous system. In: Klelhues P, Cavenee WK (eds) World Health Classification of tumours. Pathology & Genetics. Tumours of Nervous System. IARC Press, Lyon, p 153–61Google Scholar
  34. 34.
    Franks LM, Bollen A, Seeger RC et al. (1997) Neuroblastoma in adults and adolescents: an indolent course with poor survival. Cancer 79: 2028–35PubMedCrossRefGoogle Scholar
  35. 35.
    Desandes E, Lacour B, Sommelet D et al. (2006) Cancer survival among adolescents in France. Eur J Cancer 42: 403–9PubMedCrossRefGoogle Scholar
  36. 36.
    Ries LAG, Smith MA, Gurney JG et al. (1999) Cancer incidence and survival among children and adolescents: United States SEER Program 1975–1995. National Cancer Institut, SEER Program. NIH Pub. No. 99-4649, Bethesda, MD. http://seer.cancer.gov/publications/childhood/Google Scholar
  37. 37.
    Ellison LF, Pogany L, Mery LS (2007) Childhood and adolescent cancer survival: A period analysis of data from the Canadian Cancer Registry. Eur J Cancer 43: 1967–75PubMedCrossRefGoogle Scholar
  38. 38.
    Desandes E, Berger C, Tron I et al. (2008) Childhood cancer survival in France, 1990–1999. Eur J Cancer 44: 205–15PubMedCrossRefGoogle Scholar
  39. 39.
    Bleyer A (2005) The adolescent and young adult gap in cancer care and outcome. Curr Probl Pediatr Adolesc Health Care 35: 182–217PubMedCrossRefGoogle Scholar
  40. 40.
    Ministère de la Santé de la Famille et des Personnes Handicapées (2004) Circulaire DHOS/O n°2004-l6l du 29 mars 2004 relative à l’organisation des soins en cancérologie pédlatrlque. Bulletin Officiel n°2004-19Google Scholar
  41. 41.
    Ministère de la Santé et de la Protection Sociale (2005) Circulaire DHOS/O1/DGS/DGAS n° 2004-517 du 28 octobre 2004 relative à l’élaboration des SROS de l’enfant et de l’adolescent. Bulletin Officiel n°2004-52Google Scholar
  42. 42.
    Whiteson M (2003) The Teenage Cancer Trust—advocating a model for teenage cancer services. Eur J Cancer 39: 2688–93PubMedCrossRefGoogle Scholar
  43. 43.
    Dupont M, Rey-Salmon C (2002) L’enfant, l’adolescent à l’hôpital — Règles et recommandations applicables aux mineurs. Assistance Publique — Hôpitaux de Parls/Doin-Lamarre, ParisGoogle Scholar
  44. 44.
    Laurence V, Pacquement H (2006) A virtual unit: experience from the institut Curie. Arch Pediatr 13: 708–9PubMedCrossRefGoogle Scholar
  45. 45.
    Brugieres L (2006) The unit for adolescent with cancer, institut Gustave-Roussy. Arch Pediatr 13: 706–7PubMedCrossRefGoogle Scholar
  46. 46.
    Desandes E, Lacour B, Sommelet D et al. (2007) Cancer adolescent pathway in France between 1988 and 1997. Eur J Oncol Nurs 11: 74–81PubMedCrossRefGoogle Scholar
  47. 47.
    Sommelet D (2001) French pediatrie oncology: analysis of the present situation and future prospects. Arch Pediatr 8: 617–28PubMedCrossRefGoogle Scholar
  48. 48.
    Le Deley MC, Lecesne A, Brugieres L et al. (2001) Localized osteosarcoma (LO) of young and adult patients (PTS): The experience of the Institut Gustave Roussy (IGR) over a 16-year period. Med Pediatr Oncol 37: 188Google Scholar
  49. 49.
    Paulussen S, Ahrens S, Juergens HF (2003) Cure rates in Ewing tumor patients aged over 15 years are better in pediatric oncology units. Results of GPOH CESS/EICESS studies. Proc Am Soc Clin Oncol 22: 816Google Scholar
  50. 50.
    Ferrari A, Dileo P, Casanova M et al. (2003) Rhabdomyosarcoma in adults. A retrospective analysis of 171 patients treated at a single institution. Cancer 98: 571–80PubMedCrossRefGoogle Scholar
  51. 51.
    Mitchell AE, Scarcella DL, Rigutto GL et al. (2004) Cancer in adolescents and young adults: treatment and outcome in Victoria. Med J Austr 180: 59–62Google Scholar
  52. 52.
    Stock W, Sather H, Dodge RK et al. (2000) Outcomme of adolescents and young adults with ALL: a comparison of children’s cancer group (CCG) and cancer and leukemia group B (CALGB) regimens. Blood 96: 467aGoogle Scholar
  53. 53.
    Testi AM, Garzia Valsecchi M, Conter V et al. (2004) Difference in outcome of adolescents with acute lymphoblastic leukemia (ALL) enrolled in pediatric (AIEOP) and adult (GIMEMA) protocols. Blood 104: 539aGoogle Scholar
  54. 54.
    de Bont JM, Holt B, Dekker AW et al. (2004) Significant difference in outcome for adolescents with acute lymphoblastic leukemia treated on pediatric vs adult protocols in the Netherlands. Leukemia 18: 2032–5PubMedCrossRefGoogle Scholar
  55. 55.
    Boissel N, Auclerc MF, Lheritier V et al. (2003) Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J Clin Oncol 21: 774–80PubMedCrossRefGoogle Scholar
  56. 56.
    Ramanujachar R, Richards S, Hann I et al. (2007) Adolescents with acute lymphoblastic leukaemia: outcome on UK national paediatric (ALL97) and adult (UKALLXII/E2993) trials. Pediatr Blood Cancer 48: 254–61PubMedCrossRefGoogle Scholar
  57. 57.
    Woods WG, Alonzo TA, Lange BJ et al. (2001) Acute myeloid leukemia (AML) in adolescents and young adults (AYAs): a comparison of outcomes between patients treated on childhood or adult protocols. Blood 98: 462–3aGoogle Scholar
  58. 58.
    Deangelo DJ (2005) The treatment of adolescents and young adults with acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program: 123–30Google Scholar
  59. 59.
    Ramanujachar R, Richards S, Hann I et al. (2006) Adolescents with acute lymphoblastic leukaemia: emerging from the shadow of paediatric and adult treatment protocols. Pediatr Blood Cancer 47: 748–56PubMedCrossRefGoogle Scholar
  60. 60.
    Sommelet D (2004) French pediatric oncology: past and future. Arch Pediatr 11: 81–4PubMedCrossRefGoogle Scholar
  61. 61.
    Bleyer A (2007) Adolescent and young adult (AYA) oncology: the first A. Pediatr Hematol Oncol 24: 325–36PubMedCrossRefGoogle Scholar
  62. 62.
    Bleyer A, Budd T, Montello M (2006) Adolescents and young adults with cancer: the scope of the problem and criticality of clinical trials. Cancer 107: 1645–55PubMedCrossRefGoogle Scholar
  63. 63.
    Bleyer WA, Tejeda H, Murphy SB et al. (1997) National cancer clinical trials: children have equal access; adolescents do not. J Adolescent Health 21: 366–73CrossRefGoogle Scholar
  64. 64.
    Bleyer WA (2002) Cancer in older adolescents and young adults: epidemiology, diagnosis, treatment, survival, and importance of clinical trials. Med Pediatr Oncol 38: 1–10PubMedCrossRefGoogle Scholar
  65. 65.
    Liu L, Krailo M, Reaman GH et al. (2003) Childhood cancer patients’ access to cooperative group cancer programs: a population-based study. Cancer 97: 1339–45PubMedCrossRefGoogle Scholar
  66. 66.
    Klein-Geltink J, Shaw AK, Morrison HI et al. (2005) Use of paediatric versus adult oncology treatment centres by adolescents 15–19 years old: the Canadian Childhood Cancer Surveillance and Control Program. Eur J Cancer 41: 404–10PubMedCrossRefGoogle Scholar
  67. 67.
    Alvin P, Marcelli D, Fortin J et al. (2005) Partie 2: Consultation médicale. In: Marcelli D (ed) Médecine de l’adolescent (2e édition). Masson, Paris, p 55–136Google Scholar
  68. 68.
    Eden T (2006) Keynote comment: challenges of teenage and young-adult oncology. Lancet Oncol 7: 612–3PubMedCrossRefGoogle Scholar
  69. 69.
    Eden T, Smith S (2008) Symtom interval and Delays in Diagnosis. Fifth International Conference on Teenage and Young Adult Cancer Medicine, Londres, 9 juinGoogle Scholar
  70. 70.
    Thulesius H, Pola J, Hakansson A (2000) Diagnostic delay in pediatric malignancies—a population-based study. Acta Oncol 39: 873–6PubMedCrossRefGoogle Scholar
  71. 71.
    Haimi M, Peretz Nahum M, Ben Arush MW (2004) Delay in diagnosis of children with cancer: a retrospective study of 315 children. Pediatr Hematol Oncol 21: 37–48PubMedCrossRefGoogle Scholar
  72. 72.
    Goyal S, Roscoe J, Ryder WD et al. (2004) Symptom interval in young people with bone cancer. Eur J Cancer 40: 2280–6PubMedCrossRefGoogle Scholar
  73. 73.
    Albritton KH, Eden T (2008) Access to care. Pediatr Blood Cancer 50: 1094–8PubMedCrossRefGoogle Scholar
  74. 74.
    Alvin P, Marcelli D (2005) Partie 4: Maladies somatiques de long cours. Chapitre 23: Introduction à la maladie chronique. In: Alvin P, Marcelli D (eds) Médecine de l’adolescent (2nde édition). Masson, Paris, p 211–7Google Scholar
  75. 75.
    Festa RS, Tamaroff MH, Chasalow F et al. (1992) Therapeutic adherence to oral medication regimens by adolescents with cancer. I. Laboratory assessment. J Pediatr 120: 807–11PubMedCrossRefGoogle Scholar
  76. 76.
    Tamaroff MH, Festa RS, Adesman AR et al. (1992) Therapeutic adherence to oral medication regimens by adolescents with cancer. II. Clinical and psychologic correlates. J Pediatr 120: 812–7PubMedCrossRefGoogle Scholar
  77. 77.
    White-Koning M, Bertozzi-Salamon AI, Vignes M et al. (2007) Compliance to treatment of adolescents with cancer. Bull Cancer 94: 349–56PubMedGoogle Scholar
  78. 78.
    Alvin P, Marcelli D (2005) Partie 6: Approches thérapeutiques à l’adolescence. Chapitre 50: Question de l’observance à l’adolescence. In: Alvin P, Marcelli D (eds) Médecine de l’adolescent (2nde édition). Masson, Paris, p 395–404Google Scholar
  79. 79.
    Windebank KP, Spinetta JJ (2008) Do as I say or die: compliance in adolescents with cancer. Pediatr Blood Cancer 50: 1099–100PubMedCrossRefGoogle Scholar
  80. 80.
    Abrams AN, Hazen EP, Penson RT (2007) Psychosocial issues in adolescents with cancer. Cancer Treat Rev 33: 622–30PubMedCrossRefGoogle Scholar
  81. 81.
    Desandes E, Berger C, Brugières L et al. (2008) In France the challenge before us is to develop national monitoring of cancer in adolescence. Fifth International Conference on Teenage and Young Adult Cancer Medicine, Londres, 9–10 juinGoogle Scholar
  82. 82.
    Birch JM, Alston RD, Kelsey AM et al. (2002) Classification and incidence of cancers in adolescents and young adults in England 1979–1997. Br J Cancer 87: 1267–74PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag France 2009

Authors and Affiliations

  • Emmanuel Désandes
    • 1
  1. 1.Faculté de MédecineRegistre national des tumeurs solides de l’enfantVandoeuvre-lès-Nancy Cedex

Personalised recommendations